The competition between Eli Lilly and Novo Nordisk has defined the weight loss medication market for the past several years. Novo Nordisk drew first blood with semaglutide. Lilly answered with tirzepatide. Now both companies have next-generation candidates in late-stage development that could push weight loss results even further toward what was once only achievable with surgery.

Eli Lilly has retatrutide, a triple-receptor agonist. Novo Nordisk has CagriSema, a fixed-dose combination of two established molecules. These drugs represent fundamentally different scientific philosophies, and comparing them reveals a lot about where obesity medicine is heading.

What Is CagriSema?

CagriSema is not a single molecule. It is a combination of two separate drugs delivered together in a single injection:

• Semaglutide 2.4 mg: The same GLP-1 receptor agonist used in Wegovy. Suppresses appetite, slows gastric emptying, improves blood sugar control.
• Cagrilintide 2.4 mg: A long-acting amylin analog. Amylin is a hormone co-secreted with insulin from the pancreas after meals. It promotes satiety, slows gastric emptying (through a different mechanism than GLP-1), and may help regulate body weight set point.

The logic behind CagriSema is additive: if semaglutide alone produces 15% weight loss, and cagrilintide adds additional appetite suppression through a completely different hormonal pathway, the combination should produce more weight loss than either drug alone. Novo Nordisk is essentially stacking two proven approaches rather than engineering a single multi-target molecule.

What Is Retatrutide?

Retatrutide is a single molecule engineered to activate three receptors simultaneously:

• GLP-1 receptor: Appetite suppression and blood sugar control
• GIP receptor: Enhanced insulin sensitivity and metabolic signaling
• Glucagon receptor: Increased energy expenditure and hepatic fat metabolism

Rather than combining two separate drugs, Eli Lilly built one peptide that hits three targets at once. This approach requires more complex molecular engineering but results in a single compound that can be optimized as a unit.

Clinical Data Comparison

CagriSema: The REDEFINE Program

CagriSema's Phase 3 data comes from the REDEFINE clinical trial program. The headline results from REDEFINE 1 showed that CagriSema produced approximately 22.7% weight loss over 68 weeks in adults with obesity or overweight. That is notably better than semaglutide alone (about 15%) and roughly comparable to tirzepatide.

However, it is important to note that these results fell short of some earlier projections. Based on Phase 2 data and the individual performance of each component, some analysts had expected CagriSema to deliver 25%+ weight loss. The actual results, while strong, did not clearly differentiate CagriSema from tirzepatide, which was already on the market.

On the positive side, CagriSema showed strong A1C reduction in diabetic participants and a generally manageable side effect profile.

Retatrutide: The TRIUMPH Program

Retatrutide's Phase 2 data showed average weight loss of 24.2% at 48 weeks at the 12 mg dose, extending to approximately 28.7% with longer follow-up. These numbers exceeded CagriSema's Phase 3 results despite coming from an earlier and shorter trial.

Phase 3 results from the TRIUMPH program are still pending. If the Phase 3 data confirm the Phase 2 findings (even with some moderation, as is common), retatrutide would likely hold a clear efficacy advantage over CagriSema.

Side by Side

Different Scientific Philosophies

The CagriSema vs retatrutide comparison illustrates a broader debate in drug development: combination therapy vs multi-target single molecules.

The Combination Approach (CagriSema)

Novo Nordisk's strategy has clear advantages. Both semaglutide and cagrilintide have been studied individually, so their safety profiles are well characterized. The combination can be developed with a strong understanding of each component's contribution. And if one component causes issues in a particular patient, the physician has a clearer picture of what to adjust.

The potential downside is that a combination is limited by the sum of its parts. Two drugs targeting appetite suppression through different pathways is valuable, but both are still working primarily on the "intake" side of energy balance. Neither semaglutide nor cagrilintide directly increases energy expenditure.

The Single-Molecule Approach (Retatrutide)

Eli Lilly's strategy is more ambitious and potentially more rewarding. A single molecule activating three receptors offers coordinated pharmacology: the ratios of receptor activation are fixed and optimized together. The glucagon receptor component adds a dimension that CagriSema simply does not have, specifically the ability to increase metabolic rate and promote fat oxidation.

The risk is that a novel molecule has less long-term safety data. Side effects from the glucagon component (like heart rate elevation) are unique to this approach and need careful long-term monitoring.

Who Gets to Market First?

This is where things get interesting from a competitive standpoint.

CagriSema has a meaningful head start. Novo Nordisk has completed Phase 3 trials and submitted regulatory applications. FDA approval could come as early as late 2025 or early 2026, assuming no regulatory delays. Novo Nordisk also has the advantage of existing manufacturing infrastructure for semaglutide, which is one of the two components.

Retatrutide's Phase 3 trials are still enrolling and running. Even with positive results, FDA approval is more likely in the 2027 timeframe. That gives CagriSema potentially 12 to 18 months of market exclusivity as the "next-gen" option beyond tirzepatide.

However, being first does not always mean being best. If retatrutide's Phase 3 data confirm the 25%+ weight loss seen in Phase 2, it could quickly overtake CagriSema on arrival, much the way tirzepatide overtook semaglutide despite coming to market later.

Pricing Predictions

Neither drug has announced final pricing, but we can make educated guesses based on current market dynamics.

CagriSema is a combination of two biologics, which typically means higher manufacturing costs. However, Novo Nordisk will be competing directly with tirzepatide and potentially retatrutide, so they will need to price competitively. Estimates suggest CagriSema could launch in the $1,200 to $1,800 per month range, depending on the market landscape at the time of approval.

Retatrutide, as a single molecule, may have manufacturing advantages despite its molecular complexity. Eli Lilly has been aggressively investing in production capacity. Pricing will likely be in a similar range to CagriSema, possibly with a slight premium given the higher efficacy expectations.

The real cost question for patients will be insurance coverage. As the evidence base for obesity medications grows and more options enter the market, we expect insurance coverage to gradually expand. But "gradually" is the key word. Many patients will continue to face significant out-of-pocket costs in the near term.

Side Effect Profiles

Both drugs produce GI side effects, which is unavoidable with any medication that activates GLP-1 receptors. Nausea, vomiting, diarrhea, and constipation are reported with both CagriSema and retatrutide.

CagriSema has a unique consideration: injection site reactions. Cagrilintide, as an amylin analog, has been associated with more injection site reactions than GLP-1 agonists alone. In Phase 3 trials, these were mostly mild (redness, swelling at the injection site) but were more frequent than with semaglutide alone.

Retatrutide's unique consideration is the slight heart rate increase associated with glucagon receptor activation. In Phase 2 trials, this averaged 2 to 4 beats per minute and was not linked to cardiovascular events, but it remains something that Phase 3 data will need to confirm as safe over the long term.

Discontinuation rates due to side effects were broadly similar between the two drugs in their respective trials, in the range of 5 to 8%.

Beyond Weight Loss: Additional Benefits

Both medications show promise beyond the scale, but in different areas.

CagriSema benefits from semaglutide's established cardiovascular data (the SELECT trial) and the potential additive effects of cagrilintide on metabolic parameters. Amylin analogs have shown interesting effects on bone health and may help preserve bone density during weight loss, an area where more data are needed.

Retatrutide's standout secondary benefit is liver fat reduction. The glucagon receptor's role in hepatic fat metabolism gives retatrutide a dramatic advantage in this area, with Phase 2 data showing liver fat reductions of roughly 80% or more. Eli Lilly is pursuing a dedicated MASLD/MASH indication for retatrutide, which could make it a first-line treatment for fatty liver disease.

Both drugs improve blood sugar control in diabetic patients, with strong A1C reductions reported in their respective trials.

The Pipeline Context

It is worth zooming out to see how these drugs fit into each company's broader strategy.

Novo Nordisk's pipeline includes CagriSema as the next step beyond semaglutide, with additional candidates in earlier development. The company is also investing heavily in oral formulations of semaglutide (Rybelsus) and exploring other combination strategies.

Eli Lilly has a particularly deep pipeline. Beyond retatrutide, the company has orforglipron (an oral GLP-1) in Phase 3 trials. Having both an injectable triple agonist and an oral option gives Lilly flexibility to address different patient preferences and market segments.

The competition between these two companies is ultimately good for patients. It drives innovation, pushes efficacy higher, and will eventually drive costs down as more options enter the market.

What This Means for You

If you are actively seeking weight loss treatment right now, neither CagriSema nor retatrutide is available yet. The current options, including semaglutide and tirzepatide, are excellent medications that are producing meaningful, life-changing results for patients every day.

If you are thinking about the future, here is our honest take: both CagriSema and retatrutide represent significant advances. If your primary concern is maximum weight loss, retatrutide's clinical data is more impressive. If you have liver disease in addition to obesity, retatrutide has a clearer advantage in that area. If you want the first next-gen option available, CagriSema will likely reach the market sooner.

At FormBlends, we will offer the most effective, evidence-based options as they become available. Our physician team stays current with every major trial readout and regulatory milestone so that our patients always have access to the best treatments the field has to offer. Reach out to our team if you want to discuss which currently available option makes the most sense for your goals.